SCHEMBL10148264

SCHEMBL10148264

CC(C)c1ccc(OCc2ccccc2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 5/20 0.56
KDM1A O60341 4/20 0.46
S1PR5 Q9H228 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ERN1 O75460 1/20 0.44
CCR5 P51681 1/20 0.44
HTR1A P08908 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
FFAR1 O14842 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
GLRA1 P23415 1/20 0.43
CTSA P10619 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682767 0.85 MAPT (0.49) MRGPRX4MAPTMAPK1TDP1L3MBTL1
SCHEMBL20032400 0.85 MRGPRX4 (0.51) MRGPRX4KDM1AS1PR5MAPTMAPK1
SCHEMBL26581172 0.85 MRGPRX4 (0.48) MRGPRX4FFAR1
SCHEMBL12889910 0.83 GLRA1 (0.50) MRGPRX4MAPTMAPK1TDP1L3MBTL1
SCHEMBL12868786 0.83 FFAR4 (0.54) MRGPRX4MAPTMAPK1TDP1L3MBTL1
SCHEMBL24313779 0.81 FFAR1 (0.52) MRGPRX4MAPTMAPK1TDP1L3MBTL1
SCHEMBL12738664 0.81 NPC1 (0.55) MAPTHTR1AALDH1A1RAB9A
SCHEMBL17833745 0.81 SMPD1 (0.53) MAPK1HTR1AALDH1A1RAB9A
SCHEMBL14200026 0.81 MAPT (0.45) MRGPRX4MAPTMAPK1TDP1L3MBTL1
SCHEMBL10172543 0.81 NPC1 (0.52) MRGPRX4MAPTMAPK1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 US disclosed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 MRGPRX4 779/4885KDM1A 1196/4885S1PR5 467/4885
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 MRGPRX4 779/4885KDM1A 1196/4885S1PR5 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.